Caris Life Sciences (CAI) Receivables - Other (2024 - 2026)

Caris Life Sciences' Receivables - Other history runs 3 years deep, the most recent figure standing at $3.7 million for Q1 2026.

• In Q1 2026, Receivables - Other changed N/A year-over-year to $3.7 million; the TTM figure through Mar 2026 stood at $3.7 million (changed N/A YoY), while the FY2025 annual figure was $7.2 million, up 56.52% from the prior year.
• Receivables - Other was $3.7 million for Q1 2026 at Caris Life Sciences, down from $7.2 million in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $11.2 million in Q2 2025 to a low of $3.7 million in Q1 2026.
• Historically, Receivables - Other has averaged $7.3 million across 3 years, with a median of $7.2 million in 2025.
• Biggest YoY gain for Receivables - Other was 56.52% in 2025; the steepest drop was 56.52% in 2025.
• A 3-year view of Receivables - Other shows it stood at $4.6 million in 2024, then soared by 56.52% to $7.2 million in 2025, then slumped by 48.61% to $3.7 million in 2026.
• The last three Receivables - Other figures came in at $3.7 million (Q1 2026), $7.2 million (Q4 2025), and $9.9 million (Q3 2025), per Business Quant data.